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1.  Introduction 
Genome-wide association studies (GWAS) continue to be viewed as a standard approach to 
evaluating the genetic component of a variety of diseases and other phenotypes of interest [1]. 
Standard approaches to the analysis of genotype associations with quantitative phenotypes use linear 
models. 
 As suggested in Tintle et al. [2], bimodal distributions are frequently observed in continuous 
phenotype samples of metabolites, challenging the normality assumption needed in many existing 
GWAS analysis approaches. For example, red blood cell fatty acid levels have been found to 
contribute to coronary heart disease [3].  As outlined in Tintle et al. [2], it is biologically reasonable 
to consider one’s fatty acid levels as coming from a mixture of Gaussian distributions, with each of 
the two or three mean fatty acid levels determined by genetics, and variation around the mean level 
determined by other factors (e.g., diet; lifestyle). While the standard way of analyzing fatty acids 
follows the typical GWAS linear model approach, in cases where the distribution does not appear 
to be normally distributed, a log transformation is sometimes used [4]. However, this log 
transformation may fail to accurately capture the true distribution of the genotypic and phenotypic 
data since it ignores the biological reasoning for observing a non-normal distribution. It may be 
more powerful to directly model the normal mixture distribution and then test for genotype-
phenotype association. 
Recently, Kim et al. proposed a likelihood ratio test to test for association between copy number 
polymorphisms (CNP) with quantitative phenotypes and case control outcomes which followed a 
mixture of Gaussian distributions [5]. The likelihood ratio test evaluates possible differences in the 
mixing proportions of the Gaussian components by different copy number. Kim et al. showed that 
the likelihood ratio test was more powerful than a 2 x d chi-squared test with d equal to the number 
of CNP categories when the underlying data was from a mixture distribution. 
We propose adapting the Kim et al. likelihood ratio test to the standard genotype-phenotype 
testing situation for phenotypes which are distributed as a mixture of Gaussian distributions, like 
some metabolomics data  (e.g., fatty acid levels). We will provide a theoretical framework for the 
likelihood ratio test, evaluate its performance on simulated data and then apply it to a real set of 
fatty acid data from the Framingham Heart Study.  
2.  Methods 
2.1.  Notation 
Let X be a quantitative phenotype that follows a two-component Gaussian mixture distribution. 
Thus, 𝑋~𝜋𝑁(𝜇1, 𝜎
2) + (1 − 𝜋)𝑁(𝜇2, 𝜎
2) where π is the mixing parameter of the Gaussian 
components.  Let 𝜇1 and 𝜇2 be the mean parameters such that 𝜇1 ≠ 𝜇2, and we assume a common 
variance σ2 for both components. We assume 𝜋 = 𝑝01(𝑛0/N) + 𝑝11(𝑛1/N) + 𝑝21(𝑛2/N) where 𝑝𝑡1 
(t = 0, 1, 2) is the proportion of genotype t in the first component of the mixture distribution, 𝑛𝑡 (t = 
0, 1, 2) is the number of individuals with genotype t, and N is the total number of individuals.  We 
consider the null hypothesis H0 : 𝑝01 = 𝑝11 = 𝑝21  and the alternative Ha: at least one is not equal. 
Let 𝑝ф𝑖 = 𝑝0𝑖 = 𝑝1𝑖 = 𝑝2𝑖 (𝑖 = 1,2) (see Figure 1 for a visual representation). Let 𝑥𝑡𝑏 (b = 1, 2, … 
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nt) and (t = 0, 1, 2) be a random variable representing the phenotype for individual b who has 
genotype t, and let w be a vector of all 𝑥𝑡𝑏. Across all the components, the mixing proportion for 
genotype t must sum to 1 such that 𝑝𝑡1 + 𝑝𝑡2 = 1 ( t =  0 , 1, 2). 
  
 
Figure 1 visually illustrates the null and alternative models.  The black, light grey, and dark grey 
two-component mixture distributions are the phenotype distributions for the less common 
homozygote, the heterozygote and the more common homozygote, respectively. In the null 
model, 75% of the observations in each genotype are in the component with the smaller mean. 
In the alternative model, the mixing proportion for the component density with the smaller mean 
varies across genotypes.  
2.2.  Likelihood functions 
2.2.1.  Null and alternative likelihood function 
The likelihood function under the null hypothesis is:  
 
𝐿0 = ∏ (∑ 𝑝ф𝑖𝑁(𝑤𝑗|𝜇𝑖 , 𝜎
2)
2
𝑖=1
)
𝑛0+𝑛1+𝑛2
𝑗=1
 (1) 
The likelihood function under the unrestricted alternative hypothesis is: 
𝐿1 = (∏ (∑ 𝑝0𝑖𝑁(𝑥0𝑘|𝜇𝑖, 𝜎
2)
2
𝑖=1
)
𝑛0
𝑘=1
) (∏ (∑ 𝑝1𝑖𝑁(𝑥1𝑚|𝜇𝑖, 𝜎
2)
2
𝑖=1
)
𝑛1
𝑚=1
) (∏ (∑ 𝑝2𝑖𝑁(𝑥2ℎ|𝜇𝑖, 𝜎
2)
2
𝑖=1
)
𝑛2
ℎ=1
) (2) 
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2.2.2.  Restricted likelihood function 
When there is a biological understanding of the 
phenotype-genotype relationship, we recommend 
restricting the mixing proportions of the test to fit the 
biological model. We demonstrate two possible 
models, but our general method easily extends to other 
models.  The first model (LRTpro; Table 1) we consider 
is that the proportion of change between genotypes 0 
and 1 is equal to the change between genotypes 1 and 
2. Therefore, we can restrict our parameters of interest 
to 𝑝0𝑖
∗ = (𝑝01, 1 − 𝑝01), 𝑝1𝑖
∗ = (𝑝01𝑞, 1 − (𝑝01𝑞)), and 
𝑝2𝑖
∗ = (𝑝01𝑞
2 , 1 − (𝑝01𝑞
2)).  The second restricted 
model (LRTadd; Table 2) that we demonstrate describes 
an equal difference in proportions between groups 0 
and 1 and groups 1 and 2. We can restrict our 
parameters of interest to 𝑝0𝑖
∗ = (𝑝01, 1 − 𝑝01), 𝑝1𝑖
∗ =
(𝑝01 − 𝑞, 1 − (𝑝01 − 𝑞)), and 𝑝2𝑖
∗ = (𝑝01 − 2𝑞 , 1 −
(𝑝01 − 2𝑞)). Therefore, the likelihood function under 
these restrictions is: 
 
𝐿2 = (∏ (∑ 𝑝0𝑖
∗ 𝑁(𝑥0𝑘|𝜇𝑖, 𝜎
2)
2
𝑖=1
)
𝑛0
𝑘=1
) (∏ (∑ 𝑝1𝑖
∗ 𝑁(𝑥1𝑚|𝜇𝑖, 𝜎
2)
2
𝑖=1
)
𝑛1
𝑚=1
) (∏ (∑ 𝑝2𝑖
∗ 𝑁(𝑥2ℎ|𝜇𝑖, 𝜎
2)
2
𝑖=1
)
𝑛2
ℎ=1
) (3) 
 
2.2.3.  Test statistics 
Because 𝑝𝑡2 = 1 − 𝑝𝑡1 for all t, we can express each likelihood as a function of the parameters 𝜇1, 
𝜇2, 𝜎
2, and the mixing proportion(s) associated with the 𝑁(𝜇1, 𝜎
2) distribution. The resulting 
likelihood ratio test statistics are given by: 
 
𝐿𝑅𝑇𝑆 = 2(
𝑚𝑎𝑥
𝑝01, 𝑝11, 𝑝21, 𝜇1, 𝜇2, 𝜎
2  ln(𝐿1) −
𝑚𝑎𝑥
𝑝ф1, 𝜇1, 𝜇2, 𝜎
2 ln(𝐿0)) (4) 
 
 
𝐿𝑅𝑇𝑆𝑟𝑒𝑠 = 2(
𝑚𝑎𝑥
𝑝01, 𝑞, 𝜇1,, 𝜇2, 𝜎
2 ln(𝐿2) −
𝑚𝑎𝑥
𝑝ф1, 𝜇1, 𝜇2, 𝜎
2 ln(𝐿0)) (5) 
 
 
Extending the argument provided by Kim et al. the LRTS under the null hypothesis follows a central 
chi-squared distribution with the degrees of freedom equal to the difference in parameters of the 
null and alternative models [5]. Therefore, under the null hypothesis, the LRTS has a central chi-
squared distribution with 2 degrees of freedom, and the LRTSres follows a central chi-squared 
distribution with 1 degree of freedom.  
Table 1. LRTpro 
Genotype 
Component 1 
of Mixture 
Distribution 
Component 2 
of Mixture 
Distribution 
0 𝑝01  1 − 𝑝01 
1 𝑝01𝑞 1 − (𝑝01𝑞) 
2 𝑝01𝑞
2 1 − (𝑝01𝑞
2) 
   
Table 2. LRTadd 
Genotype 
Component 1 
of Mixture 
Distribution 
Component 2 
of Mixture 
Distribution 
0 𝑝01  1 − 𝑝01 
1 𝑝01 − 𝑞 1 − (𝑝01 − 𝑞) 
2 𝑝01 − 2𝑞 1 − (𝑝01 − 2𝑞) 
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2.3.  Simulation 
Using R software, we simulated 1000 datasets with 10,000 individuals per data set.  For each, 
individual, the genotype for a single SNP was generated by assuming Hardy-Weinberg equilibrium 
and minor allele frequency of either 0.05, 0.10, or 0.25. Trait values for individuals were simulated 
from two component Gaussian mixture distributions with centers one unit apart and equal variance 
of the components 𝜎2 = 0.5 or 0.75. For the mixing proportions of individuals with genotype 0, we 
used 𝑝01 = 0.9 or 𝑝01 = 0.75. We used two different biological models to simulate. In the proportional 
model we set q equal to 1, 0.9, or 0.75 so that the other mixing proportions were 𝑝11 = 𝑝01𝑞 and 
𝑝21 = 𝑝01𝑞
2. In the additive model we set q equal to 0.1 or 0.2 so that the mixing proportions were 
𝑝11 = 𝑝01 − 𝑞 and 𝑝21 = 𝑝01 − 2𝑞. Simulations were performed on all combinations of the 
parameters.  
2.4.  Statistical analysis 
To evaluate the performance of these tests in direct comparison to the standard procedure of linear 
and log-linear models, all tests were run on each simulated SNP and phenotype.  Each test produced 
a p-value, test statistic and parameter estimates. Type I error rates and power estimates were 
calculated by dividing the number of observations less than a significance level (Type I error 0.01, 
power 0.0001) by the total number of simulations. We used an Expectation Maximization (EM) 
algorithm to find the global maximums of equations (4) and (5).  One hundred random start points 
(RSP) were used for the null likelihood, and 50 RSP and one start point from the maximum of the 
null were used in the alternative [5].  The EM algorithm ran until a tolerance of 10-5 was reached or 
until 600 and 300 iterations were performed for the null and alternative models respectively.  
2.5.  Real data application  
We analyzed 20315 SNPs on chromosome 11 for 5936 individuals from the Framingham Heart 
Study using the proposed LRTpro test.  We looked exclusively at members in the offspring and 
generation 3 cohorts, all of whom are of European descent. Detailed descriptions of the sample are 
available elsewhere [6]–[9]. We looked at the red blood cell fatty acid level ratio of arachidonic acid 
(AA) to dihomo-gamma-linoleneic acid (DGLA).  These fatty acid levels were analyzed by gas 
chromatography as previously described [6].  The desaturation of AA to DGLA occurs primarily 
via enzymatic activity in the FADS gene complex on chromosome 11. We will use a Bonferroni 
correction to control the probability of type I errors at 2.47x10-6 (0.05/20315).  
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3.  Results 
3.1.  Verifying the null distribution and type I error rate 
To confirm that the null distribution of the unrestricted model is a chi-square distribution with two 
degrees of freedom and that the null distribution of the restricted model is a chi-square distribution 
with one degree of freedom, we 
examined simulations when q = 
1. In addition to examining the 
 novel tests proposed here 
(LRTpro, LRTadd) we also 
explored the type I error rates 
of the linear model, log-linear 
model, and LRT across these 
same simulations. As shown in 
Table 3 the type I error rate was 
controlled by all tests. 
3.2.  Power estimates  
 There were 48 simulations 
where the alternative 
hypothesis was true. As 
summarized in Table 4 (full 
detailed results are in 
Supplemental Table 1), the 
LRTpro has empirical power 
equal to or greater than all the 
other tests in all situations.  
LRTadd was the second most 
powerful test in all 48 
simulations. When comparing a 
linear model to the 
unconstrained LRT test directly 
there were 21 simulations 
where they had different power. 
In two-thirds of these cases (14 
out of 21), LRT had higher 
power than the linear model. 
The log-linear model never had 
an empirical power higher than 
any other test.  
Table 3. Type I Error Estimates 
  Nominal Significance Level  
 SD 0.05 0.01 0.001 
Kolmogorov-Smirnov 
test p-value1 
LRTpro 0.5 0.0497 0.011 0.0012 0.6846 
 0.75 0.0515 0.0097 0.0010 0.8832 
LRTadd 0.5 0.0472 0.0108 0.0012 0.7277 
 0.75 0.0495 0.0085 0.0008 0.7091 
LRT 0.5 0.0557 0.0108 0.0012 0.2269 
 0.75 0.0478 0.0078 0.0013 0.7435 
Linear 
Model 
0.5 0.0538 0.0107 0.0007  
0.75 0.0458 0.0070 0.0005  
Log Linear 
Model 
0.5 0.0523 0.0108 0.0007  
0.75 0.0460 0.0083 0.0007  
1As compared to a chi-square distribution.   
  
      Table 4 Power Estimates  
model q maf 𝑝01 
Linear 
Model 
Log 
 Linear  
Model 
LRTpro LRTadd LRT 
add  0.1 
0.05 
0.75 0.343 0.26 0.403 0.39 0.295 
0.9 0.44 0.316 0.631 0.624 0.508 
0.1 
0.75 0.824 0.736 0.879 0.871 0.798 
0.9 0.898 0.793 0.967 0.966 0.938 
0.25 
0.75 0.999 0.997 0.999 0.999 0.999 
0.9 0.999 0.999 1 1 1 
pro 0.9 
0.05 
0.75 0.12 0.095 0.156 0.153 0.105 
0.9 0.325 0.212 0.478 0.467 0.362 
0.1 
0.75 0.388 0.31 0.46 0.451 0.342 
0.9 0.75 0.622 0.891 0.887 0.831 
0.25 
0.75 0.904 0.844 0.936 0.932 0.892 
0.9 0.998 0.975 1 1 1 
  Power estimates for standard deviation of .75 for alpha = 0.0001 
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The choice of 0.0001 as a cutoff for our 
power estimates is arbitrary as Figure 2 
demonstrates. The LRTpro tends to have a 
smaller p-value than the linear model for all 
thresholds since almost all of the points are 
above the gray line.  
3.3.  Robustness of model selection 
Since choosing a restriction based on prior 
knowledge as is done in both LRTpro and 
LRTadd may not be possible in every 
circumstance, it may not be necessary to 
choose the exact model.  Table 4 shows that 
LRTpro and LRTadd were the most powerful 
tests even when the other model was 
simulated.  These two restrictions are of 
similar patterns, but the increase of power 
is substantial.  Therefore, choosing a model 
at least similar to the true model can 
increase the power of the test.  
3.4.  Parameter estimation 
In order to conduct the LRT, 
estimates of the underlying 
parameters of the two-component 
distribution are obtained. Table 5 
illustrates the accuracy and 
precision of the resulting estimates 
across a range of simulation settings 
for the LRTpro approach, with full 
results for all tests in supplemental 
tables 2 and 3. In general, LRTpro 
and LRTadd yielded unbiased and 
accurate estimates across settings.  
In Table  5, one can see that  LRTpro 
accurately predicted the means of 
the components both across a wide 
range of settings and with low 
variation of the estimate. LRTpro 
estimated well even when the data was simulated from the additive model. Similar results are 
obtained when estimating the mixing proportion (see Table 6) and the standard deviation of the 
components (see supplemental table 4).  
 
Table 5. Estimates of Means  for LRTpro 
True 
model 
True 
𝑝01  
q 𝜇1 
Standard 
deviation 
of 𝜇1 
𝜇2 
Standard 
deviation 
of 𝜇2 
 
 
Add 
0.75 0.1 0.0005 0.02936 1.0022 0.0401 
0.9 0.1 -0.0021 0.0240 1.0036 0.0740 
0.75 0.2 -0.0007 0.0240 1.0011 0.0349 
 0.9 0.2 -0.0020 0.0206 1.0005 0.0547 
 
 
Pro 
0.75 0.75 0.0005 0.02678 1.0005 0.0356 
0.9 0.75 -0.0014 0.0110 1.0008 0.0518 
0.75 0.9 0.0002 0.0293 1.0030 0.0400 
 0.9 0.9 -0.0025 0.02496 1.0028 0.0781 
Estimates aggregated across all settings with these parameters and all 
simulations within each setting, with the true value of 𝜇1 = 0 and 
𝜇2 = 1. 
Figure 2.  P-value comparison between LRTpro and 
the linear model. 
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3.5.  Real data results  
After analyzing 20321 SNPs on Chromosome 11 in relation to the AA/DGLA ratio, the LRTpro  test 
identified 28 SNPs as significantly associated after applying a Bonferonni multiple testing 
correction.  These 28 SNPs came from 5 different regions on chromosome 11, all of which validated 
previous GWAS findings.  Nineteen significant SNPs are in the well documented [10]–[12]FADS 
region (bp = 61622896- 61978819).   Genes in this region that contain significant SNPs include 
DAGLA, MYRF, FADS1, FADS2, FADS3, and RAB3IL1 all of which have strong biological basis 
for desaturation activity [10]. 
As an example interpretation of the results in Table 7, we first note that the significant tests all 
show similar estimates of the two components of the AA/DGLA ratio (mean of component one 
between 0.16 and 0.18; mean of component two between 0.097 and 0.101; SD of each component 
between 0.023 and 0.024). When an individual is genotyped and is the common homozygote at 
rs174549, they have a 3.6% chance of having their AA/DGLA ratio in the first component. 
However, if the individual has one less common allele, his chance increases to 18.3%, and with a 
second copy of the minor allele, it will increase to 93.7%.   
Table 6 Estimates of Mixing Proportions for LRTpro 
model True 𝑝01  q 𝑝01 sd 
True 
𝑝11  
𝑝11 sd True 𝑝21  𝑝21  sd 
 
 
Add   
0.75 0.1 0.7509  0.0280 0.65 0.5197  0.1537 0.55 0.5290  0.0625 
0.9 0.1 0.8973 0.0265 0.8 0.6134  0.2786 0.7 0.6059  0.1627 
0.75 0.2 0.7496 0.0247 0.55 0.5097  0.0582 0.35 0.5072  0.1731 
 0.9 0.2 0.8985 0.0220 0.7 0.6559   0.1220 0.5  0.5523  0.0744 
 
 
Pro   
0.75 0.75 0.7504 0.0248 0.5625 0.5390  0.0597 0.4219 0.4707  0.1188 
0.9 0.75 0.8983 0.0205 0.6750 0.6627  0.0691 0.5063 0.5139  0.0677 
0.75 0.9 0.7507 0.0284 0.6750 0.5385  0.1754 0.6075 0.5358  0.1037 
 0.9 0.9 0.8966 0.0278 0.8100 0.6290  0.2823 0.729 0.6170  0.1814 
Estimates aggregated across all settings with these parameters and all simulations within each setting. 
  Table 7. Most significant SNPs in each region 
rs# 
# of 
SNPs 
MAF Pos Gene 
LRTpro 
p-value 
𝑝01 𝑝11 𝑝21 𝜇1 𝜇2 𝜎 
rs10751124 1 0.346 85432084 DLG2 2.50x10-8 0.062 0.114 0.162 0.174 0.100 0.023 
rs11220658 1 0.350 99618283 CNTN5 4.52x10-7 0.110 0.075 0.051 0.179 0.101 0.024 
rs7129015 5 0.198 110772485  1.86x10
-7 0.105 0.059 0.034 0.179 0.101 0.024 
rs11217753 1 0.167 120181415  2.94x10
-9 0.108 0.052 0.025 0.180 0.101 0.024 
rs174549 19 0.290 61803910 FADS1 5.32x10-312 0.036 0.183 0.937 0.160 0.097 0.024 
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4.  Discussion 
GWAS typically utilize linear models, thus making an assumption about the underlying normality 
of the data. When data is not normal, a Gaussian mixture distribution may represent a statistically 
justified and biologically interpretable model of the data. We proposed a constrained likelihood ratio 
test, which across many simulation settings, was more powerful than the standard linear model and 
gave accurate parameter estimates. When applied to a real dataset, the method identified biologically 
relevant SNPs in the well understood FADS region, along with parameter estimates to aid in 
biological interpretability of the impact of the SNP. 
The general LRT framework proposed here shows reasonably good performance compared to 
the additive linear model, but can be improved upon by further constraining the model and ‘saving’ 
a degree of freedom. Our simulations suggest relatively robust performance of the constrained 
methods (LRTpro and LRTadd) to misspecification of the true model though additional simulations 
across a wider range of misspecifications are needed. 
We note that, due to the use of the EM algorithm to generate parameter estimates for use in the 
LRT, computational time for our proposed methods (3 minutes per test on a single processor with a 
sample size of 10,000) are much greater than that of the traditional linear model.  Nevertheless, with 
the increasing computational power and the limited number of high minor allele frequency SNPs, it 
is plausible to run GWAS with this method and is a reasonable option for candidate gene approaches. 
Further work is necessary to investigate potential areas of computational improvement.  
Numerous areas of future work and extension are possible. First, extensions of this work are 
needed to incorporate covariates and family structure into the method. Standard methods (e.g., first 
modeling the phenotype by covariates and/or family structure and then modeling the residuals) make 
normality assumptions and, so, may not be optimal candidates for extension in this Gaussian mixture 
modeling framework. Imputed data often provides dosages instead of discrete genotypes. Work is 
needed to extend this framework to allow for dosages in this testing framework. Further applications 
to genome wide data is necessary to fully understand the impact of this new method. Finally, 
extensions for multiple-marker testing and relaxing the equal variance assumption are also targets 
for further exploration.  
We have developed a likelihood ratio test that analyzes the differences in mixing proportions 
between genotypes. The method and null distribution were validated through simulation.  There was 
notable power increase over the more commonly used linear model, especially when we further 
increased power by restricting the model to incorporate prior biological belief. We have shown that 
this method is able to accurately predict model parameters. The model was applied to real data, and 
it replicated many previous findings while also providing more interpretable results. Further work 
is necessary to apply the model to a wider range of real metabolomics data and to investigate 
extensions of the model to handle covariates and imputed genotypes.  
 Supplemental files and R code 
All supplemental material can be found at http://homepages.dordt.edu/ntintle/mixture_test.zip. 
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